OCUPHIRE PHARMA, INC.

Analyst Reco. Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Market Closed - Nasdaq Other stock markets 01:30:00 27/06/2024 am IST			5-day change	1st Jan Change
1.535 ^USD	+0.33%		+0.33%	-49.00%

06/06	Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June	CI
10/05	Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alliance Global Partners Cuts Price Target on Ocuphire Pharma to $20 From $24, Maintains Buy Rating	20/03	MT
Cantor Fitzgerald Cuts Ocuphire Pharma's Price Target to $17 From $24, Maintains Overweight Rating	15/23/15	MT
HC Wainwright Adjusts Ocuphire Pharma's Price Target to $20 From $26, Keeps Buy Rating	26/23/26	MT
History shows stocks can weather rate hike cycle	16/22/16	RE
HC Wainwright Starts Ocuphire Pharma at Buy With $26 Price Target	24/21/24	MT
OCUPHIRE PHARMA : Alliance Global Securities Initiates Coverage on Ocuphire Pharma With Buy Rating, $25 Price Target	05/21/05	MT
OCUPHIRE PHARMA : JonesTrading Starts Ocuphire Pharma at Buy With $20 Price Target	29/21/29	MT
OCUPHIRE PHARMA : Cantor Fitzgerald Adjusts Ocuphire Pharma PT to $20 From $15, Maintains Overweight Rating	15/21/15	MT
OCUPHIRE PHARMA : Canaccord Starts Ocuphire Pharma at Buy with $22 Price Target	10/21/10	MT
OCUPHIRE PHARMA : Cantor Fitzgerald Initiates Ocuphire Pharma at Overweight With $15 Price Target	20/20/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer